Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2026 | When should anti-BCMA CAR-T be considered in AL amyloidosis?

Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses the potential role of earlier anti-BCMA CAR T-cell therapy in patients with amyloid light-chain (AL) amyloidosis who achieve insufficient responses to frontline treatment. Dr Lebel emphasizes the importance of achieving deep hematologic responses, particularly very good partial response (VGPR) or better, to support subsequent organ recovery, highlighting patients with inadequate hematologic or organ responses as potential candidates for additional treatment. This interview took place at the XX International Symposium on Amyloidosis (ISA 2026) in Montevideo, Uruguay.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.